Search Orphan Drug Designations and Approvals
-
Generic Name: | 2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-9-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone |
---|---|
Date Designated: | 01/09/2023 |
Orphan Designation: | Treatment of Pancreatic Cancer |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Qualigen Therapeutics, Inc. 2042 Corte del Nogal, Suite B Carlsbad, California 92011 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-